Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts
Open accessAbstract
In translational research described, we investigated biomarker expression by flow cytometry for MDM2 antagonist clinical response association in relapsed/refractory AML patients treated with idasanutlin-based therapy (Clinicaltrials.gov identifier: NCT01773408).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a mouse SJSA osteosarcoma xenograft model, oral administration of RG-7388 (25 mg kg−1) induced tumor growth inhibition and regression, as well as apoptosis and anti-proliferation induction.
“In a mouse SJSA osteosarcoma xenograft model, oral administration of RG-7388 (25 mg kg−1) induced tumor growth inhibition and regression, as well as apoptosis and anti-proliferation induction.401,402”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [402]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · see citing works
Self-citationResults of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works
Self-citationOncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils
Torti, D., & Trusolino, L. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100176 · Cited by 248 · see citing works
A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85 · see citing works
Yee, K. W. L., Martinelli, G., Vey, N., Dickinson, M. J., Seiter, K. P., Assouline, S. E., Drummond, M. W., Yoon, S., Kasner, M. T., Lee, J., et al. (2014) · Blood · doi:10.1182/blood.v124.21.116.116 · Cited by 76 · see citing works
Self-citationComplementary Versus Companion Diagnostics: Apples and Oranges?
Milne, C., Bryan, C. D., Garafalo, S. D., et al. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.14.84 · Cited by 34 · see citing works
Zhong, J., Chen, G., Jukofsky, L., Geho, D. H., Han, S. W., Birzele, F., Bader, S., Himmelein, L., Cai, J. J., Albertyn, Z., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13411 · Cited by 19 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Vol. 101 No. 5 (2016): May, 2016 : Online Only Articles https://doi.org/10.3324/haematol.2015.139717
Cited by
Sorted by citations
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249 · see citing works
The p53/MDM2/MDMX-targeted therapies – a clinical synopsis
Jiang, L., & Zawacka-Pankau, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2445-9 · Cited by 62 · see citing works
Seipel, K., Marques, M. A. T., Sidler, C., Mueller, B. U., & Pabst, T. (2018) · Haematologica · doi:10.3324/haematol.2018.191650 · Cited by 45 · see citing works
Hao, X., Bahia, R. K., Cseh, O., Bozek, D. A., Blake, S., Rinnenthal, J., Weyer-Czernilofsky, U., Rudolph, D., & Artee Luchman, H. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac271 · Cited by 34 · see citing works
- Authors
- Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., Theron, M., Blotner, S., Lee, J.-H., Kasner, M., Yoon, S.-S., Rueger, R., Seiter, K., Middleton, S. A., Kelly, K. R., Vey, N., Yee, K., Nichols, G., Chen, L.-C., & Pierceall, W. E.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- University of Bologna (IT)
- Peter MacCallum Cancer Centre (AU)
- Beatson West of Scotland Cancer Centre (GB)
- Jewish General Hospital (CA)
- University of Ulsan (KR)
- Thomas Jefferson University (US)
- Seoul National University (KR)
- Roche Pharma AG (Germany) (DE)
- New York Medical College (US)
- USC Norris Comprehensive Cancer Center (US)
- Institut Paoli-Calmettes (FR)
- Princess Margaret Cancer Centre (CA)
- ORCID
- Venue
- Haematologica
- Published
- 2016-02-11
- Volume
- 101
- Issue
- 5
- Pages
- e185-e188
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- PMC
- PMC5004378
- OpenAlex
- W2256505962
- Cited by
- 91
- References
- 9
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 7 · 2023: 4 · 2022: 12 · 2021: 8 · 2020: 13 · 2019: 18 · 2018: 12 · 2017: 6 · 2016: 3
- FWCI
- 12.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Haematologica (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- Touro Scholar (Touro College) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- acute myeloid leukemia, idasanutlin, RG7388, MDM2 inhibitors, relapsed/refractory AML, biomarkers, clinical response, leukemic blasts
- MeSH terms
- Blast Crisis, Female, Humans, Male, Pyrrolidines, Leukemia, Myeloid, Acute, Gene Expression Regulation, Leukemic, Proto-Oncogene Proteins c-mdm2, para-Aminobenzoates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
